ATE520033T1 - Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen - Google Patents

Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen

Info

Publication number
ATE520033T1
ATE520033T1 AT07018126T AT07018126T ATE520033T1 AT E520033 T1 ATE520033 T1 AT E520033T1 AT 07018126 T AT07018126 T AT 07018126T AT 07018126 T AT07018126 T AT 07018126T AT E520033 T1 ATE520033 T1 AT E520033T1
Authority
AT
Austria
Prior art keywords
bmaa
derivative
neurotoxic
amino acid
environmental sample
Prior art date
Application number
AT07018126T
Other languages
English (en)
Inventor
Paul Alan Cox
Sandra Banack
Susan Murch
Original Assignee
Inst Ethnomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Ethnomedicine filed Critical Inst Ethnomedicine
Application granted granted Critical
Publication of ATE520033T1 publication Critical patent/ATE520033T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00Electrophoretic profiling, e.g. for proteome analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07018126T 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen ATE520033T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49468603P 2003-08-12 2003-08-12

Publications (1)

Publication Number Publication Date
ATE520033T1 true ATE520033T1 (de) 2011-08-15

Family

ID=34215892

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03818362T ATE377758T1 (de) 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen
AT07018126T ATE520033T1 (de) 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03818362T ATE377758T1 (de) 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen

Country Status (10)

Country Link
US (5) US7256002B2 (de)
EP (2) EP1664793B9 (de)
JP (1) JP4312203B2 (de)
CN (1) CN100595588C (de)
AT (2) ATE377758T1 (de)
AU (1) AU2003296424A1 (de)
CA (1) CA2535663C (de)
DE (1) DE60317379T2 (de)
DK (1) DK1664793T3 (de)
WO (1) WO2005019830A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256002B2 (en) * 2003-08-12 2007-08-14 The Institute For Ethnomedicine Screening for neurotoxic amino acid associated with neurological disorders
US7932287B2 (en) * 2004-08-12 2011-04-26 Chemgenes Corporation Therapeutic compositions and uses
JP4709278B2 (ja) 2005-05-23 2011-06-22 エフ. ヘスス ハラルド 光変換可能な光学標識を用いる光学顕微鏡法
DE102006030976A1 (de) 2006-07-03 2008-01-17 Behrens, Meinhard, Dr. Verfahren zum qualitativen Nachweis von zugesetzten Eiweiß-Stoffen in Lebensmitteln
EP2677319B1 (de) 2008-07-09 2015-12-30 The Institute for Ethnomedicine Antikörper zum Nachweis von neurotoxischen Aminosäuren, die mit neurologischen Krankheiten assoziiert sind
CN102234240B (zh) * 2011-05-05 2014-04-09 江苏弘和药物研发有限公司 L-bmaa盐酸盐的合成方法
EP2782566B1 (de) * 2011-11-21 2021-01-06 The Institute for Ethnomedicine L-serin zur verwendung bei der behandlung neurodegenerativer erkrankungen
US8394596B1 (en) 2012-04-13 2013-03-12 Abraxis LLC Antibodies and assays for beta-N-methylamino-L-alanine
ITRM20130253A1 (it) * 2013-04-29 2014-10-30 Canox4Drug S P A Metodo per la determinazione del rame libero
CN103837620A (zh) * 2014-03-21 2014-06-04 上海硕源健标生物医学科技有限公司 一种同时检测人体血浆中多种氨基酸含量的方法
CN106053678A (zh) * 2016-08-16 2016-10-26 汤臣倍健股份有限公司 一种辅助降血糖片深加工产品中4‑羟基异亮氨酸含量的检测方法
CN107157793A (zh) * 2017-07-05 2017-09-15 芜湖凌梦电子商务有限公司 一种营养洗发香波
CN107334651A (zh) * 2017-07-05 2017-11-10 芜湖凌梦电子商务有限公司 一种营养去屑洗发香波
CN107157790A (zh) * 2017-07-05 2017-09-15 芜湖凌梦电子商务有限公司 营养去屑洗发香波
CN109524112A (zh) * 2018-12-26 2019-03-26 杭州电子科技大学 一种基于部分定向相干法的脑功能网络构建方法
CN116593706A (zh) * 2021-07-07 2023-08-15 北京常友生物科技有限公司 以β-甲氨基-L-丙氨酸为靶点在制备检测孤独症试剂盒中的应用
CN118556642A (zh) * 2024-06-05 2024-08-30 北京常友生物科技有限公司 一种利用神经毒素诱导大鼠孤独症模型的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5824554A (en) * 1994-09-09 1998-10-20 Mckay; Florine M. Detection of allergenic substances in food products
US6043283A (en) 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
ATE366259T1 (de) * 1999-03-04 2007-07-15 Praecis Pharm Inc Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
CN1341610A (zh) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——运动神经障碍相关蛋白62.15和编码这种多肽的多核苷酸
AU2002223317A1 (en) * 2000-11-03 2002-05-15 The University Of British Columbia Sterol glucoside toxins
US7256002B2 (en) * 2003-08-12 2007-08-14 The Institute For Ethnomedicine Screening for neurotoxic amino acid associated with neurological disorders

Also Published As

Publication number Publication date
US10048278B2 (en) 2018-08-14
JP4312203B2 (ja) 2009-08-12
HK1090696A1 (en) 2006-12-29
EP1860441A3 (de) 2008-03-05
ATE377758T1 (de) 2007-11-15
EP1664793B9 (de) 2008-07-16
WO2005019830A1 (en) 2005-03-03
US7256002B2 (en) 2007-08-14
DK1664793T3 (da) 2008-01-28
AU2003296424A1 (en) 2005-03-10
EP1860441A2 (de) 2007-11-28
US20070292893A1 (en) 2007-12-20
JP2007521464A (ja) 2007-08-02
CN1860369A (zh) 2006-11-08
US8541184B2 (en) 2013-09-24
EP1664793A1 (de) 2006-06-07
DE60317379D1 (de) 2007-12-20
US7901895B2 (en) 2011-03-08
EP1664793B1 (de) 2007-11-07
EP1860441B1 (de) 2011-08-10
US20070254315A1 (en) 2007-11-01
DE60317379T2 (de) 2008-09-11
US20140080140A1 (en) 2014-03-20
US7670783B2 (en) 2010-03-02
CN100595588C (zh) 2010-03-24
CA2535663C (en) 2011-02-08
US20050042686A1 (en) 2005-02-24
CA2535663A1 (en) 2005-03-03
US20110183424A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
ATE520033T1 (de) Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
DK1200832T3 (da) Annexiner og autoantistoffer anvendt som markörer for lungecancer og ösofageal cancer
ATE432470T1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
Cornachione et al. Characterization of fiber types in different muscles of the hindlimb in female weanling and adult Wistar rats
GB0510943D0 (en) Improved immunoassay methods
SI1836500T1 (sl) Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
ATE474227T1 (de) Bestimmung von felinem und caninem probnp
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
ATE504001T1 (de) Verfahren zur diagnose oder überwachung eines fehlers im zuckerstoffwechsel
EA200600539A1 (ru) Способ определения воздействия многокомпонентной смеси естественных продуктов на биологический профиль заболевания в пределах группы живых систем и разработка и контроль качества лекарственных препаратов на основе естественных продуктов
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
FI20031370A0 (fi) Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
EP1545554A4 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus
WO2004113574A3 (en) Methods for disease screening
ATE462140T1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
DE602004026439D1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
WO2007126823A3 (en) Modified metallothioneins and methods for screening and treatment of diseases associated with oxidative stress
DE602006021131D1 (de) Verfahren zur Bestimmung des Phänotyps von Zellen
EP2338988A4 (de) Beurteilungs-/screeningverfahren für erkrankungen in zusammenhang mit d-aminosäure mittels dao1-/-maus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties